ArticleScientific reports2026
AMD3100 modulates the secretome responses of human Mesenchymal Stromal Cells but not their inhibitory effect on T cell proliferation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
AMD3100 (Plerixafor) is being utilized in clinic for the mobilization of Hematopoietic Stem Cell (HSCs) from bone marrow into peripheral blood to facilitate peripheral blood sourced HSC transplantation. It is important to identify the immunomodulatory role of AMD3100 in bone marrow niche. We have investigated the effect of AMD3100 on culture expanded human bone marrow derived Mesenchymal Stem/Stromal Cells (BM MSCs) which are non-hematopoietic cells of the marrow niche. AMD3100 does not modulate the metabolic activity of BM MSCs. However, multiplex secretome analysis demonstrated that AMD3100 alters the specific innate secretory molecules of BM MSCs. AMD3100 also amplifies the chemokine secretion of MSCs upon stimulation with IFNγ and TNFα. Flow cytometry analysis identified that AMD3100 augments IFNγ and TNFα mediated induction of the immunosuppressive enzyme Indoleamine 2, 3 Dioxygenase (IDO) in human BM MSCs. Coculture functional analysis of human BM MSCs with Peripheral Blood Mononuclear Cells (PBMCs) has demonstrated that BM MSCs dose dependently inhibits the T cell proliferation and exogenous addition of AMD3100 did not modulate this inhibition. In contrast, secretory analysis showed that AMD3100 modulates the secretory responses of BM MSCs and activated PBMC cocultures. These results suggest that AMD3100 modulates the immunomodulatory effect of BM MSCs and alters the soluble milieu of marrow niche.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.